– Launched “Alnylam 2020” Guidance for
Advancement and Commercialization of RNAi Therapeutics –
– Advanced Multiple Clinical Programs and
Presented Evidence for Potential Disease-Modifying Activity for
Patisiran in Familial Amyloidotic Polyneuropathy (FAP) and ALN-AT3
in Hemophilia –
– Plans to Present New Clinical Data for
ALN-AT3 and Initial Clinical Data for ALN-CC5 in Oral Presentations
at Medical Meetings in June –
– Maintained Strong Balance Sheet with $1.45
Billion in Cash and Expects to End 2015 with Greater than $1.2
Billion in Cash –
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi
therapeutics company, today reported its consolidated financial
results for the first quarter 2015, and highlighted recent progress
in advancing its pipeline.
“These are exciting times for RNAi therapeutics and Alnylam’s
efforts to bring innovative medicines to patients. With our
‘Alnylam 2020’ strategy we aim to transition from a late-stage
clinical development company to a multi-product commercial-stage
company with a sustainable development pipeline – a profile that we
believe has rarely been achieved in the biopharmaceutical industry.
Amongst many achievements in the first quarter and recent period,
we reported promising data on potential disease modifying effects
for patisiran in Familial Amyloidotic Polyneuropathy (FAP) and
ALN-AT3 in hemophilia. Specifically, in our patisiran Phase 2
open-label extension – or ‘OLE’ – study, we generated what we
believe to be continued evidence for a possible halting of
neuropathy progression after the first 12 months of treatment, with
drug administration generally well tolerated out to 17 months.
Furthermore, recent results from our Phase 1 trial with ALN-AT3
provide initial evidence for potential correction of the hemophilia
phenotype with an encouraging tolerability profile. In aggregate,
we believe these results strengthen the bridge that we are building
between RNAi-mediated knockdown and potential clinical benefit for
patients,” said John Maraganore, Ph.D., Chief Executive Officer of
Alnylam. “We have also continued enrolling subjects in our
ALN-PCSsc Phase 1 study, and we initiated dosing in our Phase 1/2
trial with ALN-CC5. With these advancements we are now poised for a
very data-rich mid-year period, with confirmed oral presentations
of clinical results for ALN-AT3 and ALN-CC5 in June and initial
Phase 1 data for ALN-PCSsc expected in mid-2015. We look forward to
sharing these data in the weeks and months to come.”
First Quarter 2015 and Recent Significant Corporate
Highlights
- Launched “Alnylam 2020” Guidance for
advancement and commercialization of RNAi Therapeutics.
Specifically, by the end of 2020, Alnylam expects to achieve a
company profile with 3 marketed products, as well as 10 RNAi
therapeutic clinical programs – including 4 in late stages of
development – across its 3 Strategic Therapeutic Areas
(STArs).
- Advanced pipeline programs in Genetic
Medicine STAr.
- Advanced investigational RNAi
therapeutic programs for the treatment of transthyretin
(TTR)-mediated amyloidosis (ATTR amyloidosis).
- Continued enrollment in APOLLO Phase 3
study of patisiran in ATTR amyloidosis patients with Familial
Amyloidotic Polyneuropathy (FAP).
- Reported positive 12-month clinical
data from patisiran Phase 2 open-label extension (OLE) study,
showing sustained TTR knockdown of up to a mean 88% and continued
evidence for potential halting of neuropathy progression.
Specifically, a mean 2.5 point decrease in neuropathy impairment
score (mNIS+7) was observed after 12 months of patisiran
administration, comparing favorably to a 13-18 point increase in
untreated patients with similar baseline characteristics, as
estimated from published historical data sets. Patisiran was also
found to be generally well tolerated out to 17 months of drug
administration.
- Continued enrollment in ENDEAVOUR Phase
3 study of revusiran in ATTR amyloidosis patients with Familial
Amyloidotic Cardiomyopathy (FAC).
- Presented complete Phase 2 data with
revusiran in patients with TTR cardiomyopathy, showing tolerability
and an up to 98.2% knockdown of serum TTR.
- Continued dosing FAC patients in
revusiran Phase 2 OLE study designed to evaluate the tolerability
and clinical activity of revusiran with long-term dosing for up to
two years.
- Presented results from a retrospective
natural history study evaluating disease progression in ATTR
amyloidosis patients with FAC, showing a 140 meter decline in 6
minute walk distance (6MWD) at 18 months; the change in 6MWD at 18
months is a co-primary endpoint measure in ENDEAVOUR.
- Advanced ALN-AT3 for the treatment of
hemophilia and rare bleeding disorders (RBD).
- Reported positive initial results from
a small number of subjects in a Phase 1 trial of ALN-AT3, including
an up to 70% knockdown of antithrombin (AT) and initial evidence
for the potential correction of the hemophilia phenotype with an up
to 334% increase in thrombin generation and marked improvement in
whole blood clotting.
- The company announces today that it is
transitioning to once-monthly subcutaneous dose cohorts in its
ongoing Phase 1 study.
- The company also announces today that
it has completed its chronic GLP toxicology studies of ALN-AT3,
including a 9-month study in non-human primates and 6-month studies
in rat and hemophilia A mice, with No Adverse Effect Level (NOAEL)
doses that support further advancement of the program.
- Published pre-clinical study results in
Nature Medicine documenting safety, efficacy, and durability of
ALN-AT3 in rodent and non-human primate (NHP) models of
hemophilia.
- Initiated Phase 1/2 trial with ALN-CC5.
The trial is being conducted initially in normal human volunteers,
and then is expected to move to patients with paroxysmal nocturnal
hemoglobinuria (PNH).
- Advanced pipeline programs in
Cardio-Metabolic Disease STAr
- Continued dosing in Phase 1 trial with
ALN-PCSsc in normal human volunteers with elevated LDL-C at
baseline.
- The company announces today that it has
completed the single ascending dose (SAD) phase of the study and
has initiated the multi-dose (MD) phase with or without statin
co-administration.
- Formed new agreement with Isis
Pharmaceuticals, extending the companies’ decade-long alliance to
lead the development and commercialization of RNA
therapeutics.
- Completed successful public offering of
common stock, with concurrent private placements from Genzyme,
totaling $567 million in net proceeds.
- Signed a 295,000 square foot lease with
an affiliate of BioMed Realty for Class A laboratory and office
space in Cambridge for the company’s future corporate
headquarters.
- The company announces today that
Cynthia Clayton, Vice President of Investor Relations and Corporate
Communications, will be transitioning from Alnylam to pursue
personal interests. Michael Mason, Alnylam’s Vice President of
Finance, will lead the company’s investor relations area on an
interim basis. The company has initiated an external search to
identify a new person for this role. Joshua Brodsky, Senior
Manager, Investor Relations and Corporate Communications, will
report to Mr. Mason during the transition period.
“We want to thank Cynthia for her decade-long leadership of
Alnylam’s corporate communications team. We are very sad to see her
go, but are happy that she’ll have a chance to pursue her personal
interests,” said John Maraganore. “In the meanwhile, Mike Mason
will assume acting leadership of our investor relations team while
we conduct a search for Cynthia’s replacement.”
Upcoming Events in Mid-2015
- Alnylam announces today that it plans
to present additional data from its ALN-AT3 Phase 1 trial in
subjects with hemophilia at the International Society on Thrombosis
and Haemostasis (ISTH) 2015 Congress, being held June 20 – 25, 2015
in Toronto, in an oral presentation on Tuesday, June 23 at 2:30
p.m. ET.
- The company also announces today that
it plans to present initial single ascending dose (SAD) cohort data
from its ALN-CC5 Phase 1/2 trial in normal human volunteers at the
20th Congress of the European Hematology Association (EHA), being
held June 11 – 14, 2015 in Vienna, Austria, in an oral presentation
on Sunday, June 14 at 8:45 a.m. Central European Summer Time (2:45
a.m. ET).
- In addition, during mid-2015, Alnylam
plans to:
- Initiate Phase 1 trial with ALN-AS1 in
development for the treatment of hepatic porphyrias
- Present initial data from Phase 1 trial
of ALN-PCSsc in development for the treatment of
hypercholesterolemia
- File Clinical Trial Application (CTA)
for ALN-AAT in development for the treatment of alpha-1 antitrypsin
(AAT) deficiency-associated liver disease
- Select Development Candidate (DC) for
ALN-GO1 in development for the treatment of Primary Hyperoxaluria
Type 1 (PH1)
“Alnylam continues to maintain a very strong balance sheet, with
approximately $1.45 billion in cash as of the end of the
first quarter of 2015,” said Michael Mason, Vice President,
Finance & Treasurer. “Our cash balance was bolstered in the
quarter with net proceeds of approximately $567 million that
resulted from a public offering and concurrent private placements
from Genzyme. This financing resulted in a balance sheet that
allows us to invest in a broad pipeline of RNAi therapeutics across
all three Alnylam STArs, which we believe will enable us to realize
our ‘Alnylam 2020’ goals. As for financial guidance this year, we
remain on track to end 2015 with greater than $1.2 billion in
cash.”
Financials
Cash, Cash Equivalents and Total Marketable Securities
At March 31, 2015, Alnylam had cash, cash equivalents and total
marketable securities of $1.45 billion, as compared to $881.9
million at December 31, 2014.
In January 2015, Alnylam sold an aggregate of 5,447,368 shares
of its common stock through an underwritten public offering at a
price to the public of $95.00 per share. As a result of the
offering, Alnylam received aggregate net proceeds of $496.4
million.
In January 2015, in connection with our public offering
described above, Genzyme exercised its right under the investor
agreement between Alnylam and Genzyme, to purchase, in concurrent
private placements, 744,566 shares of common stock, at the public
offering price of $95.00 per share, resulting in proceeds to
Alnylam of $70.7 million.
Under the investor agreement, Genzyme also has the right each
January to purchase a number of shares of Alnylam’s common stock
based on the number of shares issued during the previous year for
compensation-related purposes. Genzyme exercised this right to
purchase 196,251 shares of our common stock on January 22, 2015 for
approximately $18.3 million.
The exercise of these rights allowed Genzyme to maintain its
current ownership level of Alnylam common stock of approximately
12%.
Non-GAAP Net Loss
The non-GAAP net loss for the first quarter of 2015 was $50.8
million, or $0.62 per share on both a basic and diluted basis as
compared to a non-GAAP net loss of $26.3 million, or $0.39 per
share on both a basic and diluted basis for the same period in the
previous year. The non-GAAP net loss for the first quarter of 2014
excludes the $224.7 million charge to in-process research and
development expense for the purchase of the Sirna RNAi assets from
Merck, described below, for which there is no corresponding expense
for the first quarter of 2015.
GAAP Net Loss
The net loss according to accounting principles generally
accepted in the U.S. (GAAP) for the first quarter of 2015 was $50.8
million, or $0.62 per share on both a basic and diluted basis
(including $8.2 million, or $0.10 per share of non-cash stock-based
compensation expense), as compared to a net loss of $250.9 million,
or $3.70 per share on both a basic and diluted basis (including
$5.6 million, or $0.08 per share of non-cash stock-based
compensation expense), for the same period in the previous
year.
Revenues
Revenues were $18.5 million for the first quarter of 2015, as
compared to $8.3 million for the first quarter of 2014. Revenues
for the first quarter of 2015 included $5.6 million of revenues
from the company’s collaboration with Monsanto, $5.5 million from
the company’s alliance with Takeda Pharmaceuticals Company Limited,
$2.0 million for the company’s alliance with The Medicines Company,
$1.8 million from the company’s alliance with Genzyme and $3.6
million from research reagent licenses and other sources. The
increase in revenues in the first quarter of 2015 compared to the
first quarter of the previous year was due primarily to revenue
recognized in connection with the September 2014 amendment of our
remaining performance obligations under the Monsanto agreement, as
well as services performed in connection with our performance
obligations under agreements with The Medicines Company and
Genzyme. In addition, net revenues from collaborators increased due
to the achievement of certain non-recurring milestones from other
sources. The company expects net revenues from collaborators to
decrease during the remainder of 2015 on a comparative basis due
primarily to the completion of our performance obligations under
the Monsanto agreement in February 2015 and the planned completion
of our revenue amortization under the Takeda agreement in May
2015.
Research and Development Expenses
Research and development (R&D) expenses were $58.0 million
in the first quarter of 2015 which included $5.3 million of
non-cash stock-based compensation, as compared to $43.8 million in
the first quarter of 2014, which included $3.7 million of non-cash
stock-based compensation. The increase in R&D expenses in the
first quarter of 2015 as compared to the first quarter of the prior
year was due primarily to additional expenses related to the
significant advancement of certain of our clinical and pre-clinical
programs. In addition, compensation, non-cash stock-based
compensation and related expenses increased during the first
quarter of 2015 as compared to the first quarter of 2014 due
primarily to a significant increase in headcount during the period
as we expand and advance our development pipeline. Offsetting these
increases was a decrease in license fees during the first quarter
of 2015 as compared to the first quarter of 2014. The company
expects that research and development expenses will increase for
the remainder of 2015.
In-Process Research and Development Expense
In the first quarter of 2014, the company incurred a $224.7
million charge to in-process research and development expense in
connection with the purchase of the Sirna RNAi assets from Merck.
Specifically, at the closing of the transaction, the company paid
Merck $25.0 million in cash and issued 2,142,037 shares of the
company’s common stock. The company issued an additional 378,007
shares of common stock to Merck upon the completion of certain
technology transfer activities, which was completed in the second
quarter of 2014.
General and Administrative Expenses
General and administrative (G&A) expenses were $12.7 million
in the first quarter of 2015, which included $2.9 million of
non-cash stock-based compensation, as compared to $8.9 million in
the first quarter of 2014, which included $1.9 million of non-cash
stock-based compensation. The increase in G&A expenses in the
first quarter of 2015 as compared to the first quarter of the prior
year was due primarily to an increase in consulting and
professional services related to an increase in general business
activities. In addition, compensation, non-cash stock-based
compensation and related expense increased during the first quarter
of 2015 as compared to the first quarter of 2014 due primarily to
an increase in headcount during the period as compared to the prior
year period. For the remainder of 2015, the company expects that
general and administrative expenses will remain consistent with the
first quarter of 2015.
Benefit from Income Taxes
The company had a benefit from income taxes of $0.4 million for
the first quarter of 2015 as compared to $17.9 million in the first
quarter of 2014. The decrease was due to the corresponding income
tax benefit associated with the sale of the company’s common stock
at execution of the 2014 Genzyme collaboration. In addition, the
company also recorded a reduced income tax benefit for the increase
in the value of the company’s investment in Regulus that the
company carried at fair market value during the same respective
period.
Conference Call InformationManagement will provide an
update on the company, discuss first quarter 2015 results, and
discuss expectations for the future via conference call on
Thursday, May 7, 2015 at 4:30 p.m. ET. To access the call, please
dial 877-312-7507 (domestic) or
631-813-4828 (international) five minutes prior to the start
time and refer to conference ID 38203671. A replay of the call will
be available beginning at 7:30 p.m. ET on May 7, 2015. To access
the replay, please dial 855-859-2056 (domestic) or
404-537-3406 (international), and refer to conference ID
38203671.
About RNAiRNAi (RNA interference) is a revolution in
biology, representing a breakthrough in understanding how genes are
turned on and off in cells, and a completely new approach to drug
discovery and development. Its discovery has been heralded as “a
major scientific breakthrough that happens once every decade or
so,” and represents one of the most promising and rapidly advancing
frontiers in biology and drug discovery today which was awarded the
2006 Nobel Prize for Physiology or Medicine. RNAi is a natural
process of gene silencing that occurs in organisms ranging from
plants to mammals. By harnessing the natural biological process of
RNAi occurring in our cells, the creation of a major new class of
medicines, known as RNAi therapeutics, is on the horizon. Small
interfering RNA (siRNA), the molecules that mediate RNAi and
comprise Alnylam's RNAi therapeutic platform, target the cause of
diseases by potently silencing specific mRNAs, thereby preventing
disease-causing proteins from being made. RNAi therapeutics have
the potential to treat disease and help patients in a fundamentally
new way.
About GalNAc Conjugates and Enhanced Stabilization Chemistry
(ESC) GalNAc ConjugatesGalNAc-siRNA conjugates are a
proprietary Alnylam delivery platform and are designed to achieve
targeted delivery of RNAi therapeutics to hepatocytes through
uptake by the asialoglycoprotein receptor. Alnylam’s Enhanced
Stabilization Chemistry (ESC) GalNAc-conjugate technology enables
subcutaneous dosing with increased potency, durability, and a wide
therapeutic index, and is being employed in several of Alnylam’s
genetic medicine programs, including programs in clinical
development.
About LNP TechnologyAlnylam has licenses to Tekmira LNP
intellectual property for use in RNAi therapeutic products using
LNP technology.
About Alnylam PharmaceuticalsAlnylam is a
biopharmaceutical company developing novel therapeutics based on
RNA interference, or RNAi. The company is leading the translation
of RNAi as a new class of innovative medicines. Alnylam’s pipeline
of investigational RNAi therapeutics is focused in 3 Strategic
Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline
of RNAi therapeutics for the treatment of rare diseases;
Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics
toward genetically validated, liver-expressed disease targets for
unmet needs in cardiovascular and metabolic diseases; and Hepatic
Infectious Disease, with a pipeline of RNAi therapeutics that
address the major global health challenges of hepatic infectious
diseases. In early 2015, Alnylam launched its “Alnylam 2020”
guidance for the advancement and commercialization of RNAi
therapeutics as a whole new class of innovative medicines.
Specifically, by the end of 2020, Alnylam expects to achieve a
company profile with 3 marketed products, 10 RNAi therapeutic
clinical programs – including 4 in late stages of development –
across its 3 STArs. The company’s demonstrated commitment to RNAi
therapeutics has enabled it to form major alliances with leading
companies including Merck, Medtronic, Novartis, Biogen, Roche,
Takeda, Kyowa Hakko Kirin, Cubist, GlaxoSmithKline, Ascletis,
Monsanto, The Medicines Company, and Genzyme, a Sanofi company. In
addition, Alnylam holds an equity position in Regulus Therapeutics
Inc., a company focused on discovery, development, and
commercialization of microRNA therapeutics. Alnylam scientists and
collaborators have published their research on RNAi therapeutics in
over 200 peer-reviewed papers, including many in the world’s top
scientific journals such as Nature, Nature Medicine, Nature
Biotechnology, Cell, New England Journal of Medicine, and The
Lancet. Founded in 2002, Alnylam maintains headquarters in
Cambridge, Massachusetts. For more information about Alnylam’s
pipeline of investigational RNAi therapeutics, please visit
www.alnylam.com.
Alnylam Forward Looking StatementsVarious statements in
this release concerning Alnylam’s future expectations, plans and
prospects, including without limitation, Alnylam’s expectations
regarding its “Alnylam 2020” guidance, Alnylam’s views with respect
to the potential for RNAi therapeutics, including patisiran,
revusiran, ALN-AT3, ALN-CC5, ALN-PCSsc, ALN-AS1, ALN-AAT, and
ALN-GO1, its expectations with respect to the timing, execution,
and success of its clinical and pre-clinical trials, the expected
timing of regulatory filings, including its plan to file IND or IND
equivalent applications and/or initiate clinical trials for ALN-AAT
and ALN-AS1, its expectations regarding reporting of data from its
clinical and pre-clinical studies, including its studies for
patisiran, revusiran, ALN-AT3, ALN-CC5, and ALN-PCSsc, as well as
other research programs and technologies, its plans regarding
commercialization of RNAi therapeutics, and Alnylam’s expected cash
position as of December 31, 2015, constitute forward-looking
statements for the purposes of the safe harbor provisions under The
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those indicated by these forward-looking
statements as a result of various important factors, including,
without limitation, Alnylam’s ability to manage operating expenses,
Alnylam’s ability to discover and develop novel drug candidates and
delivery approaches, successfully demonstrate the efficacy and
safety of its drug candidates, the pre-clinical and clinical
results for its product candidates, which may not be replicated or
continue to occur in other subjects or in additional studies or
otherwise support further development of product candidates,
actions of regulatory agencies, which may affect the initiation,
timing and progress of clinical trials, obtaining, maintaining and
protecting intellectual property, Alnylam’s ability to enforce its
patents against infringers and defend its patent portfolio against
challenges from third parties, obtaining regulatory approval for
products, competition from others using technology similar to
Alnylam’s and others developing products for similar uses,
Alnylam’s ability to obtain additional funding to support its
business activities and establish and maintain strategic business
alliances and new business initiatives, Alnylam’s dependence on
third parties for development, manufacture, marketing, sales and
distribution of products, the outcome of litigation, and unexpected
expenditures, as well as those risks more fully discussed in the
“Risk Factors” filed with Alnylam’s most recent Annual Report on
Form 10-K filed with the Securities and Exchange Commission (SEC)
and in other filings that Alnylam makes with the SEC. In addition,
any forward-looking statements represent Alnylam’s views only as of
today and should not be relied upon as representing its views as of
any subsequent date. Alnylam explicitly disclaims any obligation to
update any forward-looking statements.
Alnylam Pharmaceuticals, Inc. Unaudited Condensed
Consolidated Statements of Comprehensive Loss (In thousands,
except per share amounts)
Three Months Ended March 31,
2015 2014 Net revenues
from collaborators $ 18,537 $ 8,275
Operating expenses: Research and development (1) 58,035
43,758 In-process research and development — 224,656 General and
administrative (1) 12,724 8,925 Total
operating expenses 70,759 277,339 Loss
from operations (52,222 ) (269,064 )
Other income
(expense): Interest income 1,014 333 Other income (expense)
— (82 ) Total other income 1,014
251 Loss before income taxes (51,208 ) (268,813 )
Benefit from income taxes 431 17,870
Net loss $ (50,777 ) $ (250,943 )
Net loss per
common share - basic and diluted $ (0.62 ) $ (3.70 )
Weighted average common shares used to compute basic and diluted
net loss per common share 82,074 67,786
Comprehensive
loss Net loss $ (50,777 ) $ (250,943 ) Unrealized gain on
marketable securities, net of tax 3,622 5,313
Comprehensive loss $ (47,155 ) $ (245,630 ) (1)
Non-cash stock-based compensation expenses included in operating
expenses are as follows: Research and development $ 5,346 $ 3,681
General and administrative 2,890 1,910
Alnylam Pharmaceuticals, Inc.
Unaudited GAAP to Non-GAAP
Reconciliation: Net Loss and Net Loss Per Share
(In thousands, except per share
amounts)
For the Three Months Ended
March 31, 2015 2014 GAAP net loss $ (50,777)
$ (250,943) Adjustment: In-process research and development expense
—
224,656
Non-GAAP net loss $ (50,777)
$ (26,287) GAAP net loss per common share –
basic and diluted $ (0.62)
$ (3.70) Adjustment (as detailed above)
—
3.31
Non-GAAP net loss per common share – basic and diluted $ (0.62)
$ (0.39)
Use of Non-GAAP Financial MeasuresThe company supplements
its condensed consolidated financial statements presented on a GAAP
basis by providing additional measures that are considered
“non-GAAP” financial measures under applicable SEC rules. These
non-GAAP financial measures are not prepared in accordance with
generally accepted accounting principles in the United States
(GAAP) and should not be viewed in isolation or as a substitute for
GAAP net loss and basic and diluted net loss per common share.
The company evaluates items on an individual basis, and
considers both the quantitative and qualitative aspects of the
item, including (i) its size and nature, (ii) whether or not it
relates to the company’s ongoing business operations, and (iii)
whether or not the company expects it to occur as part of its
normal business on a regular basis. In the first quarter of 2014,
the company’s Non-GAAP net loss and Non-GAAP loss per common share
– basic and diluted financial measures excludes the in-process
research and development expense of $224.7 million related to the
purchase of the Sirna RNAi assets from Merck. The company believes
that the exclusion of this expense provides management and
investors with supplemental measures of performance that better
reflect the underlying economics of the company’s business. In
addition, the company believes the exclusion of this expense is
important in comparing current results with prior period results
and understanding projected operating performance. Management uses
these non-GAAP financial measures to establish budgets and
operational goals and to manage the company’s business.
ALNYLAM PHARMACEUTICALS, INC.
UNAUDITED CONDENSED CONSOLIDATED
BALANCE SHEETS
(In thousands, except share
amounts)
March 31, December 31,
2015 2014 Cash, cash equivalents
and total marketable securities $ 1,450,754 $ 881,929 Billed and
unbilled collaboration receivables 10,107 39,937 Prepaid expenses
and other current assets 13,206 9,739 Deferred tax assets 33,667
31,667 Property and equipment, net 21,166 21,740 Investment in
equity securities of Regulus Therapeutics Inc.
99,890 94,583
Total
assets $ 1,628,790 $
1,079,595 Accounts payable, accrued expenses and other liabilities
$ 31,917 $ 38,791 Deferred tax liabilities 33,667 31,667 Total
deferred revenue 60,665 66,854 Total deferred rent 6,031 6,016
Total stockholders’ equity (84.2 million
and 77.2 million commonshares issued and outstanding and at March
31, 2015 and December 31,2014, respectively)
1,496,510
936,267
Total liabilities and stockholders' equity
$ 1,628,790 $ 1,079,595
This selected financial information should be read in
conjunction with the consolidated financial statements and notes
thereto included in Alnylam’s Annual Report on Form 10-K which
includes the audited financial statements for the year ended
December 31, 2014.
Alnylam Pharmaceuticals, Inc.Michael Mason,
617-551-8327Vice President, Finance and TreasurerorJoshua Brodsky,
617-551-8276Senior Manager, Investor Relations andCorporate
Communications
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2024 to May 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From May 2023 to May 2024